These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21193338)

  • 1. Coexistence of β-thalassemia and polycythemia vera.
    Lopes da Silva R; Silva M
    Blood Cells Mol Dis; 2011 Feb; 46(2):171-2. PubMed ID: 21193338
    [No Abstract]   [Full Text] [Related]  

  • 2. Polycythemia vera with uncommon presentations.
    Dincer AP; Subramanian S; Goksel M
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):665-6; discussion 667. PubMed ID: 16258466
    [No Abstract]   [Full Text] [Related]  

  • 3. Pruritic indurated plaques on the legs of a 62-year-old woman--quiz case. Polycythemia vera (PCV).
    Prodanovic EM; Frater JL; Burkemper NM; Hurley MY
    Arch Dermatol; 2011 Jan; 147(1):109-14. PubMed ID: 21242405
    [No Abstract]   [Full Text] [Related]  

  • 4. Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.
    Martinez-Lopez J; Jimenez A; Sanchez-Calero J; Monteagudo D; Urbanowicz M; Cañamares-Orbis I; Cortijo-Cascajares S; Ayala R
    Ann Hematol; 2015 Jul; 94(7):1237-9. PubMed ID: 25791242
    [No Abstract]   [Full Text] [Related]  

  • 5. [Polycythemia vera].
    Gemünden C; Gerber B
    Praxis (Bern 1994); 2012 May; 101(10):631-9, 641; quiz 640. PubMed ID: 22565553
    [No Abstract]   [Full Text] [Related]  

  • 6. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient.
    Kouroupi E; Cassinat B; Schlageter MH; Dosquet C; Kiladjian JJ; Chomienne C
    Am J Hematol; 2012 Jun; 87(6):646. PubMed ID: 22473461
    [No Abstract]   [Full Text] [Related]  

  • 8. Unanswered questions in polycythaemia vera.
    Finazzi G
    Eur J Haematol Suppl; 2007 Oct; (68):18-21. PubMed ID: 17727560
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 11. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
    Fruchtman SM; Mack K; Kaplan ME; Peterson P; Berk PD; Wasserman LR
    Semin Hematol; 1997 Jan; 34(1):17-23. PubMed ID: 9025158
    [No Abstract]   [Full Text] [Related]  

  • 12. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of parathyroidectomy in JAK2 mutation negative polycythemia vera.
    Kulaylat AN; Jung EE; Saunders BD
    Int J Hematol; 2014 Dec; 100(6):615-8. PubMed ID: 25209606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
    Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
    Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of polycythemia vera with hydroxyurea.
    Tatarsky I; Sharon R
    Semin Hematol; 1997 Jan; 34(1):24-8. PubMed ID: 9025159
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
    Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 57-Year-Old Woman With Abdominal Pain.
    Malikowski TM; Podboy AJ; Sweetser S
    Mayo Clin Proc; 2017 Aug; 92(8):1278-1282. PubMed ID: 28647225
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
    Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
    Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.